High-dose carboplatin with etoposide in patients with recurrent thymoma

The Indiana University experience

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Thymoma is a chemotherapy-sensitive tumor with a 30-50% 5-year survival in previously untreated patients. Unfortunately, durable CRs with salvage chemotherapy are rarely observed. We initiated a phase II trial of high-dose carboplatin and etoposide in patients with relapsed thymoma or thymic carcinoma. All patients had progressive disease (PD) after initial or salvage chemotherapy, but were not cisplatin-refractory. PBSCs were mobilized using 10 μg/kg/day G-CSF. Patients received carboplatin 700 mg/m2 and etoposide 750 mg/m2 i.v. on days -5, -4, -3. Five patients were enrolled and evaluated after tandem transplants 4 weeks apart. All patients had pleural-based and lung parenchymal metastasis, one or two prior surgeries and two or more courses of prior cisplatin-based chemotherapy regimens. Chemotherapy was well tolerated, although grade IV hematological toxicity occurred in all patients. Progression-free survival following HDC ranged from 3.5 to 16.5 months. One patient maintained a CR for 12.8 months, then died from an unrelated cause. With a minimum of 2 years follow-up for all patients, three of five patients remain alive at 26+, 36+, and 49+ months. High-dose carboplatin and etoposide in relapsed thymoma is feasible with acceptable toxicity; however, these limited data do not appear superior to standard-dose salvage therapy.

Original languageEnglish
Pages (from-to)435-438
Number of pages4
JournalBone Marrow Transplantation
Volume28
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Thymoma
Carboplatin
Etoposide
Drug Therapy
Cisplatin
Salvage Therapy
Granulocyte Colony-Stimulating Factor
Disease-Free Survival
Neoplasm Metastasis
Transplants
Lung

Keywords

  • Autologous stem cell transplantation
  • Relapse disease
  • Thymoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{657fcc1d341b406db9bae8a867a767fb,
title = "High-dose carboplatin with etoposide in patients with recurrent thymoma: The Indiana University experience",
abstract = "Thymoma is a chemotherapy-sensitive tumor with a 30-50{\%} 5-year survival in previously untreated patients. Unfortunately, durable CRs with salvage chemotherapy are rarely observed. We initiated a phase II trial of high-dose carboplatin and etoposide in patients with relapsed thymoma or thymic carcinoma. All patients had progressive disease (PD) after initial or salvage chemotherapy, but were not cisplatin-refractory. PBSCs were mobilized using 10 μg/kg/day G-CSF. Patients received carboplatin 700 mg/m2 and etoposide 750 mg/m2 i.v. on days -5, -4, -3. Five patients were enrolled and evaluated after tandem transplants 4 weeks apart. All patients had pleural-based and lung parenchymal metastasis, one or two prior surgeries and two or more courses of prior cisplatin-based chemotherapy regimens. Chemotherapy was well tolerated, although grade IV hematological toxicity occurred in all patients. Progression-free survival following HDC ranged from 3.5 to 16.5 months. One patient maintained a CR for 12.8 months, then died from an unrelated cause. With a minimum of 2 years follow-up for all patients, three of five patients remain alive at 26+, 36+, and 49+ months. High-dose carboplatin and etoposide in relapsed thymoma is feasible with acceptable toxicity; however, these limited data do not appear superior to standard-dose salvage therapy.",
keywords = "Autologous stem cell transplantation, Relapse disease, Thymoma",
author = "Nasser Hanna and Gharpure, {V. S.} and Rafat Abonour and Kenneth Cornetta and Patrick Loehrer",
year = "2001",
doi = "10.1038/sj.bmt.1703181",
language = "English",
volume = "28",
pages = "435--438",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - High-dose carboplatin with etoposide in patients with recurrent thymoma

T2 - The Indiana University experience

AU - Hanna, Nasser

AU - Gharpure, V. S.

AU - Abonour, Rafat

AU - Cornetta, Kenneth

AU - Loehrer, Patrick

PY - 2001

Y1 - 2001

N2 - Thymoma is a chemotherapy-sensitive tumor with a 30-50% 5-year survival in previously untreated patients. Unfortunately, durable CRs with salvage chemotherapy are rarely observed. We initiated a phase II trial of high-dose carboplatin and etoposide in patients with relapsed thymoma or thymic carcinoma. All patients had progressive disease (PD) after initial or salvage chemotherapy, but were not cisplatin-refractory. PBSCs were mobilized using 10 μg/kg/day G-CSF. Patients received carboplatin 700 mg/m2 and etoposide 750 mg/m2 i.v. on days -5, -4, -3. Five patients were enrolled and evaluated after tandem transplants 4 weeks apart. All patients had pleural-based and lung parenchymal metastasis, one or two prior surgeries and two or more courses of prior cisplatin-based chemotherapy regimens. Chemotherapy was well tolerated, although grade IV hematological toxicity occurred in all patients. Progression-free survival following HDC ranged from 3.5 to 16.5 months. One patient maintained a CR for 12.8 months, then died from an unrelated cause. With a minimum of 2 years follow-up for all patients, three of five patients remain alive at 26+, 36+, and 49+ months. High-dose carboplatin and etoposide in relapsed thymoma is feasible with acceptable toxicity; however, these limited data do not appear superior to standard-dose salvage therapy.

AB - Thymoma is a chemotherapy-sensitive tumor with a 30-50% 5-year survival in previously untreated patients. Unfortunately, durable CRs with salvage chemotherapy are rarely observed. We initiated a phase II trial of high-dose carboplatin and etoposide in patients with relapsed thymoma or thymic carcinoma. All patients had progressive disease (PD) after initial or salvage chemotherapy, but were not cisplatin-refractory. PBSCs were mobilized using 10 μg/kg/day G-CSF. Patients received carboplatin 700 mg/m2 and etoposide 750 mg/m2 i.v. on days -5, -4, -3. Five patients were enrolled and evaluated after tandem transplants 4 weeks apart. All patients had pleural-based and lung parenchymal metastasis, one or two prior surgeries and two or more courses of prior cisplatin-based chemotherapy regimens. Chemotherapy was well tolerated, although grade IV hematological toxicity occurred in all patients. Progression-free survival following HDC ranged from 3.5 to 16.5 months. One patient maintained a CR for 12.8 months, then died from an unrelated cause. With a minimum of 2 years follow-up for all patients, three of five patients remain alive at 26+, 36+, and 49+ months. High-dose carboplatin and etoposide in relapsed thymoma is feasible with acceptable toxicity; however, these limited data do not appear superior to standard-dose salvage therapy.

KW - Autologous stem cell transplantation

KW - Relapse disease

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=0035165158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035165158&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703181

DO - 10.1038/sj.bmt.1703181

M3 - Article

VL - 28

SP - 435

EP - 438

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -